The CPACS trial includes a lead-in dose of Bisantrene as a single agent to measure changes in m6A levels. Demonstrating that altered m6A levels correlate with tumor responses and synergy with anthracyclines will validate Bisantrene as an entirely new drug class. Drugs from a new class that meet breakthrough therapy criteria receive particular attention due to their innovative nature. Clinical validation of Bisantrene as an FTO inhibitor, along with its effects on m6A in cancer, redefines Bisantrene's entire clinical history. The phase 3 clinical trial in breast cancer, where Bisantrene outperformed doxorubicin and mitoxantrone, gains significant attention, especially if Bisantrene demonstrates synergy with anthracyclines and proven cardioprotection.
This will accelerate rapidly if the data aligns with our expectations.
General Comments / Chat, page-10961
-
- There are more pages in this discussion • 521 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.69 |
Change
0.010(0.60%) |
Mkt cap ! $287.1M |
Open | High | Low | Value | Volume |
$1.69 | $1.70 | $1.65 | $89.01K | 53.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 2342 | $1.69 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.70 | 5 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 2342 | 1.685 |
1 | 3664 | 1.680 |
1 | 5077 | 1.660 |
2 | 1805 | 1.650 |
1 | 612 | 1.635 |
Price($) | Vol. | No. |
---|---|---|
1.695 | 5 | 1 |
1.700 | 11000 | 1 |
1.730 | 2399 | 1 |
1.750 | 952 | 2 |
1.775 | 1328 | 1 |
Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online